UK: Fighting The Opioid Crisis – A UK Perspective

Last Updated: 9 October 2018
Article by Matthew Thaxter

By now, it is likely that most people have heard about the ongoing opioid crisis in the US, as barely a day goes by without some form of media coverage. Recent stories have also emerged of a significant upward trend in opioid prescriptions in the UK. This blog explores some of the drivers behind the US crisis, and how likely we are to see a similar epidemic here in the UK.

What are opioids?

Opioids are generally used for moderate and severe pain relief, and are usually only available with a doctor's prescription. Opioids work by attaching to receptors in the brain to release signals blocking the perception of pain. Some opioids, including codeine, oxycodone, morphine sulphate and heroin are derived from the opium poppy, while others, known as synthetic opioids such as tramadol and fentanyl, are manufactured to simulate similar effects to natural opioids.1 

What are the statistics?

The US consumes roughly 80 per cent of the global supply of prescription opioids.2 However, a considerable amount of this consumption is misused, with overdose from opioids the leading cause of death for Americans under 50.3 In total, opioid deaths are at a record high throughout the US, with 72,000 deaths attributed to opioid overdose in 2017 – a 10 per cent annual increase.4 Within the UK, the Office for National Statistics (ONS) data for drug-related deaths in England and Wales in 2017 indicates that there were 3,756 deaths – the highest since records began. Opioids accounted for over half of these deaths in 2017, at 1,985 deaths, which was a 2.6 per cent decline from the previous year (see Figure 1).5

Figure 1. Deaths from opioids, England and Wales - 2008-2017

Loss of life, however, is just one of a number of far reaching effects of the US opioid crisis. For example, the number of babies born with Neonatal Abstinence Syndrome (NAS) – a drug withdrawal syndrome among infants exposed to opioids while in the womb – has quadrupled over the past 15 years. Additionally, almost three quarters of US states have seen unprecedented increases in the number of children entering foster care, with parental substance abuse cited as the primary driver.6 Recent research has also suggested that the increase in opioid prescriptions from 1999 to 2015 could account for 20 per cent of the decline in men's labour force participation over the same period.7

What caused the US crisis?

A report in 2016, from the Deloitte Center for Government Insights - Fighting the opioid crisis: An ecosystem approach to a wicked problem, provides a comprehensive overview of the history, challenges and current and other suggested solutions to the opioid and heroin epidemic that today 'touches nearly every American'. It notes that,' just two decades ago, when opioids were mainly prescribed as end-of-life cancer drugs, most Americans felt little connection to the problem of opioid use and heroin abuse'. It also notes that 'there is no agreement on the root cause of the problem. That the complex reality is that the crisis is driven by many problems, such as: lack of alternative pain management treatments for sufferers of chronic pain, loose prescribing practices, inadequate training for physicians and consumers, and treatment programmes and reimbursement strategies that haven't evolved to support the longer-term treatment needed for addiction to opioids'. Finally, it also concludes that such a broad crisis requires an ecosystem approach, from engaging new partners in the fight and aligning action across the ecosystem, to using a portfolio of interventions, driving innovation, and using markets to support sustainable solutions.8

Fast forward to 2018, and the Trump Administration has now launched numerous initiatives in a bid to tackle the opioid epidemic and support patients who are suffering with opioid use disorder (OUD). For example, in August 2018, the US Food and Drug Administration (FDA) released new scientific recommendations aimed at encouraging increased innovation and more widespread development of novel medication-assisted treatments (MAT) for people with OUD. New draft guidance issued at the same time outline new ways for drug developers to consider measuring and demonstrating the effectiveness and benefits of new or existing MAT products. Regular adherence to MAT can help patients to gain control over their use of opioids, and coupled with relevant social, medical and psychological services is very effective for OUD treatment.9 Moreover, in May 2018 the FDA also announced an innovation challenge to address the national opioid epidemic. Specifically, the FDA is looking to the developer community to build digital health technologies, such as medical devices, diagnostic tests and mobile apps to help stem the opioid crisis. The intent is to provide unique approaches to detecting, treating and preventing addiction, addressing diversion and treating pain.10

What is happening in the UK?

The worrying trend of increased prescribing has also been observed in the UK, with over 24 million prescriptions of opioids in 2017 – an increase of 10 million since 2007.11 Furthermore, fatalities from the synthetic opioid fentanyl were up by almost 30 per cent in 2017.12 However, despite these worrying statistics, there are key differences between the US and UK healthcare systems which could work to protect the UK from the devastating crisis currently being experienced in the US.

Firstly, doctors in the UK operate under much more stringent oversight of prescribing than their US counterparts, with patients generally having to register with a GP practice to obtain an NHS prescription. With the overwhelming majority of opioid prescriptions in the UK on the NHS, any doctor seen to be prescribing excessively will be investigated as this will show up on the practice or trust's prescribing data. Nevertheless, the fact of the matter is that prescribing has increased. Furthermore, in the US, where universal healthcare is not provided, patients are required to purchase their own health insurance, and many of these policies do not encourage alternative non drug-related pain management services such as physical therapy, in contrast to the NHS where these services are more widely available.13

What can be done to tackle the crisis?

Ultimately, a change in culture is required regarding the treatment of chronic pain with recognition given to the fact that chronic pain is a condition requiring ongoing management, rather than an acute disease that can only be treated and cured with drugs. Moreover, recent research suggests that treatment with opioid medication offers no advantages over non-opioid medications for improving long-term pain-related function.14 Many academic papers suggest that opioid use should be limited to patients with chronic cancer pain, and short-lived acute pain. However, 90 per cent of opioid prescriptions in the UK are for non-cancer chronic pain.15

Another avenue to explore could be personalised medicine, following findings suggesting that genetic factors play a key role in determining who develops an addiction to opioids. One such study suggests that genetic testing may be able to predict a person's risk of developing an addiction to opioids.16 Armed with this type of insight in the future, physicians may be able to make more informed decisions, providing patients with a more personalised approach to pain management and possibly prevent the development of opioid addiction in those highest at risk.

With chronic pain affecting an estimated 28 million people in the UK, 8 million of whom suffer with enough pain to be disabling, it is clear that alternatives to opioids are required. Educating healthcare professionals regarding alternative non-opioid treatments for chronic pain is vital, as is investing in non-drug related pain management services in order to make these more readily available. Finally, further research into non-opioid alternatives for use in chronic pain management should also be explored, in order to arm healthcare professionals with more treatment options for their patients.

















The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions